White Paper
Leveraging Real-World Data to Estimate Race and Ethnicity Representation in Clinical Trial Design
Mar 30, 2023

Diversity of patients who are ultimately impacted by approval and use of drugs in the real world is often lacking in the clinical trials’ population group. The FDA reports many racial and ethnic groups continue to be underrepresented, and the actual mix of populations for the conditions being addressed in clinical trials is not reflected. Inadequate participation from clinically relevant populations can lead to insufficient information related to product safety and efficacy and undermine its use among understudied populations.

In this Insights Brief, IQVIA experts evaluate how best to set diversity goals and ensure clinical trials are more accessible by taking a proactive approach to diversity and inclusion that begins at the earliest stages of epidemiological review and protocol design.

Related solutions

Contact Us